Keyron
1 known investors
Keyron develops ForePass®, a fully reversible, non-invasive endoscopic device designed to treat severe obesity, Type 2 diabetes, and NASH by replicating the metabolic effects of gastric bypass surgery without incisions. The device targets Class II and III obesity patients in the US and EU5 who are unsuitable for or unwilling to undergo traditional surgery or respond inadequately to pharmaceutical interventions.
Digital HealthHealthtechMedical Devices
Investors · 1
In the news
- Raiders sign third-round pick DE Keyron Crawfordraiders.com · 2026
- Keyron appoints new Chief Executive Officer - BioSpacebiospace.com · 2023
- Investors - Keyronkeyron.com · 2022
- Keyron - 2025 Company Profile, Team, Funding, Competitors & Financials - Tracxntracxn.com · 2021